William B. Dalton

William B. Dalton

Oncology
1800 Orleans Street
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Journal: Leukemia & lymphoma
Published: February 15, 2026

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Journal: Haematologica
Published: February 15, 2026

Targeting EZH2 Oncogenic Splicing: Decoding the Regulatory Network and Antisense Correction.

Targeting EZH2 Oncogenic Splicing: Decoding the Regulatory Network and Antisense Correction.

Journal: bioRxiv : the preprint server for biology
Published: January 16, 2026

Targeting EZH2 oncogenic splicing: decoding the regulatory network and antisense correction.

Targeting EZH2 oncogenic splicing: decoding the regulatory network and antisense correction.

Journal: Genes & development
Published: January 01, 2026

Distinct and convergent effects of SF3B1 mutations in human breast cancer.

Distinct and convergent effects of SF3B1 mutations in human breast cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 07, 2025

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Journal: Leukemia research
Published: June 25, 2025

Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML.

Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML.

Journal: bioRxiv : the preprint server for biology
Published: June 04, 2025

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.

Journal: Blood neoplasia
Published: April 10, 2025

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.

Journal: Haematologica
Published: January 24, 2025

Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma.

Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma.

Journal: Hepatology (Baltimore, Md.)
Published: August 12, 2024

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.

Journal: Blood advances
Published: July 24, 2023

Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.

Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.

Journal: Haematologica
Published: July 07, 2023
Showing 1-12 of 40

Last Updated: 09/26/2026